On November 27, 2025, the SIGMA Consortium welcomed the Drug Safety Research Unit (DSRU) as its newest member. Based in the UK, DSRU is an independent academic unit internationally recognized for its expertise in pharmacovigilance and pharmacoepidemiology. The organization conducts post-authorization safety studies (PASS), risk management, and real-world evidence research to contribute to the safe and effective use of medicines. DSRU collaborates with regulatory authorities, pharmaceutical companies, and healthcare professionals to help improve patient safety globally.
With decades of experience in observational studies, benefit-risk evaluation and methodological research to strengthen pharmacovigilance DSRU’s work is anchored in delivering high-quality pharmacovigilance and pharmacoepidemiology services, providing expert consulting, and advancing education and training for professionals in the field. This multifaceted approach enables DSRU to address complex challenges in medicine safety and contribute meaningfully to public health. This new membership will contribute to strengthening SIGMA’s collaborative efforts and amplifying the Consortium’s impact across the sector. The SIGMA Consortium warmly welcomes this new member and looks forward to collaborating with Dr. Linda Härmark and the rest of the DSRU Team!
